We're advancing in the diagnosis of Alzheimer's and other illnesses related to ageing

We work together with scientific research projects to prevent Alzheimer's and other illnesses related to ageing, delay their appearance and improve people's health and quality of life.

ALFA study (Alzheimer and families) of the Pasqual Maragall Foundation

Since 2008 this pioneering project has focused its work on producing a study aimed at the early diagnosis of Alzheimer's.

  • Achievement: The Estudio Alfa for cognitive and genetic assessment had 2,743 healthy participants aged between 45 and 65 to gather information that helps us prevent or delay the appearance of Alzheimer's.

Gr@ACE Project – Genomic Research on Alzheimer’s disease

GR@ACE will be carried out over three years (from 2016 to 2019) and has the backing of ObraSocial ”la Caixa” and the Grífols Foundation.
The study is based on the application of high resolution genomic techniques to identify a new generation of genes that will provide data to design new treatments for Alzheimer’s disease. This is the Alzheimer's disease research project with the most genomic samples carried out to date in Spain.

  • Milestone: GR@ACE is the leading study in Spain in genomic research on Alzheimer’s disease in terms of the number of patient samples, more than 4000. It will help identify new genetic targets for treating this disease.

Identification of epigenetic biomarkers in Alzheimer's disease, in peripheral blood. Fundación Miguel Servet and Centro de Investigación Biomédica Navarrabiomed

Dr Maite Mendioroz, director of the Neuroepigenetics Laboratory, neurologist with vast experience in neurological disease biomarker research.

Alzheimer's disease is a chronic neurodegenerative disorder with a huge health, economic and social impact. However, tools for diagnosis and treatment are still very scarce.

The aim of the project is to identify epigenetic biomarkers in patients with Alzheimer's disease that can contribute to improving the diagnosis, prognosis and treatment of the disease.

The project is aimed at patients in early stages and the population at risk of developing the disease. In the case of the Spanish population, it is estimated that half of the people over sixty years old (approximately five million people) present the first stages of the disease in their brain, even though they have not developed any symptoms or only very mild symptoms.

A transversal case-control study is carried out, recruiting a group of seventy-five patients who meet criteria of "probable Alzheimer's disease dementia" and seventy-five control patients matched by age and gender. This seeks to create a non-invasive diagnostic test that can be carried out on accessible tissue and will help to improve early diagnosis and detection of the disease.